{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-22-000015","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.582403+00:00","generated_at":"2026-06-25T23:57:56.032454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance","bullets":["Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).","Net income $146.9M (+95% YoY); Adjusted EBITDA $187.0M (77% margin).","Nucleic Acid Production base business (ex-COVID CleanCap) revenue grew 55% YoY.","Full-year 2022 revenue guidance reaffirmed; Adjusted EBITDA and EPS guidance raised.","Deborah Barbara appointed Vice President, Business Development and Strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-22-000015","json":"https://secwatch.observer/filing/0001823239-22-000015.json","markdown":"https://secwatch.observer/filing/0001823239-22-000015.md","text":"https://secwatch.observer/filing/0001823239-22-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/0001823239-22-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/mrvi-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:57:56.032454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}